COVID-19 in Immunocompromised Cancer Patients: A Case Series and Review of the Literature.
Cancer Control
; 28: 10732748211044361, 2021.
Article
in English
| MEDLINE | ID: covidwho-1440880
ABSTRACT
The global pandemic of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has presented newfound challenges to the oncology community regarding management of disease progression in immunocompromised and cancer patients. Further, the large influx of COVID-19 patients has overwhelmed healthcare facilities, limited access to intensive care unit beds and ventilators, and canceled elective surgeries causing disruptions to the cancer care continuum and re-organization of oncological care. While it is known that the potential threat of infection is greatest in elderly patients (>60 years of age) and patients with underlying comorbidities, there is still insufficient data to determine the risk of COVID-19 in cancer patients. Given the immunosuppressive status in cancer patients arising from chemotherapy and other comorbidities, management of COVID-19 in this patient population carries a unique set of challenges. We report three cases of COVID-19 in immunocompromised cancer patients and discuss the challenges in preventing, diagnosing, and treating this vulnerable group.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunocompromised Host
/
SARS-CoV-2
/
COVID-19
/
Neoplasms
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
Cancer Control
Journal subject:
Neoplasms
Year:
2021
Document Type:
Article
Affiliation country:
10732748211044361
Similar
MEDLINE
...
LILACS
LIS